Literature DB >> 11120378

Contribution of sodium channel and sodium/hydrogen exchanger to sodium accumulation in the ischemic myocardium.

K Tanonaka1, A Takasaki, H Kajiwara, S Takeo.   

Abstract

Contribution of sodium channels and sodium/hydrogen exchangers (NHEs) to sodium accumulation during ischemia in the ischemic/reperfused heart was examined. Ischemia increased the myocardial sodium. Reperfusion elicited a further increase in the myocardial sodium, which was associated with little recovery of the left ventricular developed pressure (LVDP) of the perfused heart. Treatment with tetrodotoxin or dimethylamirolide (DMA) dose-dependently attenuated the ischemia- and reperfusion-induced increase in myocardial sodium and enhanced the post-ischemic recovery of the LVDP. There was an inverse relationship between the increase in myocardial sodium during ischemia and the post-ischemic recovery of the LVDP.The myocardial sodium accumulation during ischemia is mainly attributed to sodium influx through sodium channels and NHEs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11120378     DOI: 10.1016/s0306-3623(00)00057-4

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  3 in total

1.  Combined blockade of the Na+ channel and the Na+/H+ exchanger virtually prevents ischemic Na+ overload in rat hearts.

Authors:  Michiel ten Hove; Maurits A Jansen; Marcel G J Nederhoff; Cees J A Van Echteld
Journal:  Mol Cell Biochem       Date:  2006-11-11       Impact factor: 3.396

2.  Protective effect of propranolol on mitochondrial function in the ischaemic heart.

Authors:  Takeshi Iwai; Kouichi Tanonaka; Sayaka Kasahara; Rie Inoue; Satoshi Takeo
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

3.  Preservation of mitochondrial function may contribute to cardioprotective effects of Na+/Ca2+ exchanger inhibitors in ischaemic/reperfused rat hearts.

Authors:  K Motegi; K Tanonaka; Y Takenaga; N Takagi; S Takeo
Journal:  Br J Pharmacol       Date:  2007-06-04       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.